Sledovať
Alessandra Pivetti
Alessandra Pivetti
Azienda Ospedaliero Universitaria Policlinico di Modena
Overená e-mailová adresa na: aou.mo.it
Názov
Citované v
Citované v
Rok
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19
E Villa, R Critelli, S Lasagni, A Melegari, A Curatolo, C Celsa, ...
Blood advances 5 (3), 662-673, 2021
542021
Role of vitamin D in liver disease and complications of advanced chronic liver disease
F Ravaioli, A Pivetti, L Di Marco, C Chrysanthi, G Frassanito, ...
International Journal of Molecular Sciences 23 (16), 9016, 2022
262022
Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma
L Di Marco, A Pivetti, FG Foschi, R d’Amico, F Schepis, C Caporali, ...
Liver Transplantation 29 (5), 559-563, 2023
162023
From listing to recovery: a review of nutritional status assessment and management in liver transplant patients
F Ravaioli, N De Maria, L Di Marco, A Pivetti, R Casciola, C Ceraso, ...
Nutrients 15 (12), 2778, 2023
82023
Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation
S Lasagni, F Leonardi, A Pivetti, L Di Marco, F Ravaioli, M Serenari, ...
Frontiers in Oncology 12, 960808, 2022
62022
Upregulation of the oestrogen target gene SIX1 is associated with higher growth speed and decreased survival in HCV-positive women with hepatocellular carcinoma
RM Critelli, F Milosa, A Romanzi, S Lasagni, G Marcelli, L Di Marco, ...
Oncology letters 24 (5), 395, 2022
32022
Long-Term SARS-CoV-2 Antibody Seroprevalence in Blood Donors, Italy
M Ferrari, L Di Marco, A Pivetti, S Paduano, C Vecchi, V Bernabucci, ...
Emerging Infectious Diseases 29 (7), 1479, 2023
22023
Prognostic significance of hypoxic and metabolic gene profiling in hepatocellular carcinoma
F Milosa, RM Critelli, S Lasagni, A Pivetti, L Di Marco, D Romagnoli, ...
Liver Cancer International 2 (1), 15-26, 2021
22021
Abstract PO003: Combination therapy with Nivolumab/Bevacizumab is safe and effective in patients with recurrent hepatocellular carcinoma after liver transplant
L Di Marco, A Pivetti, N De Maria, FG Foschi, D Romagnoli, F Casari, ...
Clinical Cancer Research 28 (17_Supplement), PO003-PO003, 2022
12022
Safety and clinical activity of combination treatment with regorafenib and milciclib in liver transplant patients with hepatocellular carcinoma recurrence.
A Pivetti, L Di Marco, L Bristot, F Milosa, RM Critelli, N De Maria, ...
Journal of Clinical Oncology 38 (15_suppl), e16634-e16634, 2020
12020
Suppressing, stimulating and/or inhibiting: the evolving management of HCC patient after liver transplantation
L Di Marco, A Romanzi, A Pivetti, N De Maria, F Ravaioli, M Salati, E Villa, ...
Critical Reviews in Oncology/Hematology, 104607, 2024
2024
The Neoangiogenic Transcriptomic Signature Impacts Hepatocellular Carcinoma Prognosis and Can Be Triggered by Transarterial Chemoembolization Treatment
RM Critelli, F Casari, A Borghi, G Serino, C Caporali, P Magistri, A Pecchi, ...
Cancers 16 (20), 3549, 2024
2024
Hepatitis delta virus (hdv) replication through hbv integrants in hcc recurrence after liver transplantation
L Di Marco, N De Maria, A Pivetti, A Colecchia, A Romanzi, A Spallanzani, ...
Digestive and Liver Disease 56, S328-S329, 2024
2024
Differential Impact of Tumor Endothelial Angiopoietin-2 and Podoplanin in Lymphatic Endothelial Cells on HCC Outcomes with Tyrosine Kinase Inhibitor Treatment According to Sex
S Lasagni, RM Critelli, F Milosa, D Saltini, F Schepis, A Romanzi, F Dituri, ...
Biomedicines 12 (7), 1424, 2024
2024
SAT-060 Needle tract seeding of hepatocellular carcinoma after liver transplantation: a single center experience
C Sicuro, G Frassanito, L Di Marco, A Pivetti, R Odorizzi, C Guidetti, ...
Journal of Hepatology 80, S389-S390, 2024
2024
SAT-490 Competitive risk analysis of spleen stiffness measurement with a spleen-dedicated module (SSM@ 100 Hz) for predicting de-novo HCC occurrence in cACLD patients: a …
F Ravaioli, L Colecchia, E Dajti, A Vestito, A Gobbato, F Lami, M Renzulli, ...
Journal of Hepatology 80, S399-S400, 2024
2024
OC. 05.1: COMPETITIVE RISK ANALYSIS OF SPLEEN STIFFNESS MEASUREMENT WITH A SPLEEN-DEDICATED MODULE (SSM@ 100HZ) FOR PREDICTING DE-NOVO HCC OCCURRENCE IN CACLD PATIENTS: A …
F Ravaioli, L Colecchia, E Dajti, A Gobbato, M Renzulli, M Serenari, ...
Digestive and Liver Disease 56, S148-S149, 2024
2024
Competitive Risk Analysis of Spleen Stiffness Measurement with a Spleen-Dedicated Module (SSM@ 100Hz) for Predicting de-novo HCC Occurrence in cACLD Patients: A Prospective 5 …
F Ravaioli, L Colecchia, E Dajti, A Vestito, A Gobbato, F Lami, M Renzulli, ...
Digestive and Liver Disease 56, S80-S81, 2024
2024
A machine learning enabled score based on large varices predicts 5-and 10-year hepatocellular carcinoma (HCC) development in a 12-year prospective cohort of patients with …
S Ascari, R Sardone, F Castellana, F Schepis, V Baldaccini, F Semellini, ...
Digestive and Liver Disease 55, S221, 2023
2023
Combination therapy with Nivolumab/Bevacizumab is safe and effective in patients with recurrent hepatocellular carcinoma after liver transplant
L Di Marco, A Pivetti, N De Maria, FG Foschi, D Romagnoli, F Casari, ...
CLINICAL CANCER RESEARCH 28 (17), 2022
2022
Systém momentálne nemôže vykonať operáciu. Skúste to neskôr.
Články 1–20